Over thirty years, my research has focused on hereditary cancer risk, primarily in breast, ovarian cancer or lynch syndrome.  Areas of study have included biomarker and innovative strategies for surveillance for ovarian cancer, surgical protocols for ovarian cancer prevention and gaps and health inequities in germline testing and management of risk as well as health outcomes after early menopause in women who undergo guideline recommended oophorectomy to prevent ovarian cancer.  My most recent project was piloting a program of direct oncologist germline testing of women with ovarian cancer.  This led to increased uptake of germline testing as well as decreased time to test result.  As a result of the successful findings, this pilot was translated into a clinical management change in the entire organization of Kaiser Permanente Northern California and the direct ordering by oncologist is now a practice expanding to cancers other than ovarian, including breast cancer.